# Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

> **NCT01599104** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1161 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** LCZ696
- **DRUG:** Olmesartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01599104
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 1161 (ACTUAL)
- **Last updated:** 2015-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01599104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01599104, "Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01599104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*